Lupin to acquire French generics injectables developer Medisol

Indian pharma company Lupin has agreed to acquire Medisol, a French pharmaceutical company, for an undisclosed price.

Established in 2011, Medisol is engaged in developing generics injectable products and commercializing them in pharmacies and hospitals in France.

The acquisition will help Lupin get access to a portfolio of seven injectable products of Medisol, which are across four therapeutic areas of pain management, cardiovascular diseases, anti-inflammatory, and obstetrics.

Thierry Volle — Lupin EMEA President said: “The acquisition of Medisol marks a significant milestone in Lupin’s journey to strengthen our injectables portfolio in France, the second-largest market in Europe for injectables.

“Medisol’s unique product portfolio complements our existing range, enabling us to offer our customers an even more robust selection of high-quality products. This acquisition underscores our unwavering commitment to expanding our presence in the EMEA region and providing superior healthcare to patients.”

The deal is subject to receipt of approval from the French Ministry of Economy and Finance.